​Ossiform - Announces rebrand

Ossiform - Announces rebrand​

ODENSE, January 5th, 2022 - Ossiform​, We Print Bone™, is pleased to announce that it has completed its rebranding. With the approaching launch of its first bone implant for human use, the Company has rapidly grown and matured, and the rebranding marks a further step in expanding Ossiform’s commercialization activities.

The new Ossiform name and brand echoes the Company’s endeavor to supply bone implant products that resemble real bone with wide-ranging benefits for patients and healthcare providers.

Ossiform has developed a disruptive and patented technology to provide 3D printed, natural, and patient specific P3D Bone implants that remodel into real living bone. With the first research products launched, and a solid organization and production established to produce and supply the P3D Bone, the Company now launches its new name, website, and logo. Meanwhile, Ossiform’s focus remains on preparing its patient specific implants for the US$4.48 billion bone implant market and bringing its 3D printed R&D product, the P3D Scaffolds, into laboratories worldwide. ​

“It has been such an exiting journey the last two years with Particle3D, and I am proud to take part in the rebranding of the Company giving life to Ossiform and laying the path for the launch of the first P3D Bone. Now the name is emphasizing what we do – We Print Bone – and according to plan we are ready to launch later this year”, says CEO, Thea Wulff Olesen.

While the Company’s former name, Particle3D, was rooted in its novel powder particle-based 3D printing technology, it no longer fits the rapidly developing business that is looking toward an early commercialization of P3D Bone in the USA. The first P3D Bone implant for human use is expected to reach the market in the second half of 2022. This first bone implant is customizable in size and will be provided in standardized shapes for orthopedic surgery.

Visit ossiform.com to explore the new website and brand.

About Ossiform

Ossiform is a Danish MedTech company founded on proprietary technology to 3D print patient specific, natural, and resorbable bone implants. This enables fast ingrowth of bone tissue, remodeling into real living bone, and results in fewer complications. The technology is further used to provide 3D printed R&D products for enhancing bone research, develop implants with additives, such as antibiotics or other pharmaceuticals, and even has applications in industries outside healthcare. Website: Ossiform - We Print Bone

For more information, please contact:

Ossiform:​

Thea Wulff Olesen, CEO​

two@ossiform.com

Tel.: +45 26 32 63 32​

That's why, We Print Bone

Our mission is to provide 3D printed natural bone implants to reduce complications, improve functional outcomes, and obtain faster recovery

Tailored mix of cortical and cancellous components, optimized for bone regeneration and indication-specific biomechanics

Fully remodels into new vascularized bone, leaving nothing but natural bone

Patient matched designed with the patient's uniqueness and biomechanical factors in mind

Resorbable material with structural support, tuned to offer balanced rates of resorption and new bone ingrowth 

P3D Bone Extremities Wedge – approval process ongoing

Our first 3D printed, resorbable P3D Bone with modifiable dimensions and a bone-like morphology

P3D Bone - further products under development

The next generation of resorbable and structural bone implants

We Print Bone​™

Contact us here

Contact us for questions, general inquiries, or to request a quote.
We strive to provide you with highest quality service and expertise in medical 3D printing.

Please make sure all required fields are filled out correctly

Do you have questions?

Give us a call or send us an email: info@ossiform.com

We will get back to you as soon as possible.​

logo - hvid u. baggrund

Ossiform ApS - We Print Bone™

​Oslogade 1, 5000 Odense C​, Denmark

CVR. 38838512

  youtube (1)  facebook  linkedin  twitter_2  instagram

Copyright © 2024 Ossiform​. All rights reserved.